4 news items
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
MYGN
23 May 24
is currently available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators and is expected to launch
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
MYGN
21 Mar 24
and academic or pharmaceutical investigators. "The sensitivity and detection limit achieved with Precise MRD allows it to perform across a wide range
Myriad Genetics And National Cancer Center Hospital East In Japan Collaborate On Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
MYGN
27 Feb 24
with the esteemed NCCHE team on the SCRUM-MONSTAR-SCREEN-3 study. Investigators at NCCHE have been at the forefront of MRD research, leading some of the most
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
MYGN
27 Feb 24
. Investigators at NCCHE have been at the forefront of MRD research, leading some of the most groundbreaking and influential trials as part of SCRUM-MONSTAR-SCREEN
- Prev
- 1
- Next